Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 1

Depression in Parkinson’s disease: Health risks, etiology, and treatment options

Authors Pasquale G Frisina, Joan C Borod, Nancy S Foldi, Harriet R Tenenbaum

Published 8 February 2008 Volume 2008:4(1) Pages 81—91

DOI https://doi.org/10.2147/NDT.S1453

Pasquale G Frisina1,2, Joan C Borod3,4, Nancy S Foldi3,5, Harriet R Tenenbaum6

1Leir Parkinson’s Disease Program, The Jewish Home and Hospital Lifecare System, New York, NY, USA; 2Department of Geriatrics and Adult Development, Mount Sinai School of Medicine, New York, NY, USA; 3Department of Psychology, Queens College and The Graduate Center of the City University of New York (CUNY), Flushing, NY, USA; 4Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA; 5Department of Medicine, Winthrop-University Hospital, State University of New York, Stony Brook School of Medicine; 6Department of Psychology, Kingston University, Kingston upon Thames, UK

Abstract: Depression is found in about 30%–40% of all patients with Parkinson’s disease (PD), but only a small percentage (about 20%) receive treatment. As a consequence, many PD patients suffer with reduced health-related quality of life. To address quality of life in depressed PD patients, we reviewed the literature on the health correlates of depression in PD (eg, cognitive function), etiology of depression in PD, and treatment options (ie, antidepressants, electroconvulsive therapy, and psychotherapy). The current review is unique in its focus on psychosocial aspects, as well as neuropathological factors, of depression in PD. Overall, we conclude that neurochemical (eg, serotonin) and psychosocial factors (eg, coping style, self-esteem, and social support) contribute to the affective disturbances found in this neuropsychiatric population. Therefore, we recommend that a multidisciplinary (eg, pharmacotherapeutic, psychoeducational, and/or psychotherapeutic) approach to treatment be taken with depressed PD patients.

Keywords: depression, Parkinson’s disease, health outcomes, treatment options

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Biocomposite nanofibrous strategies for the controlled release of biomolecules for skin tissue regeneration

Gandhimathi C, Venugopal JR, Bhaarathy V, Ramakrishna S, Kumar SD

International Journal of Nanomedicine 2014, 9:4709-4722

Published Date: 8 October 2014

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer

Deng L, Ke X, He Z, Yang D, Gong H, Zhang Y, Jing X, Yao J, Chen J

International Journal of Nanomedicine 2012, 7:5053-5065

Published Date: 19 September 2012

Carbon nanotube composites for glucose biosensor incorporated with reverse iontophoresis function for noninvasive glucose monitoring

Tai-Ping Sun, Hsiu-Li Shieh, Congo Tak-Shing Ching, et al

International Journal of Nanomedicine 2010, 5:343-349

Published Date: 4 May 2010

Homocysteine and carotid intima-media thickness in ischemic stroke patients are not correlated

George Ntaios, Christos Savopoulos, Apostolos Hatzitolios, Ippoliti Ekonomou, Evangelos Destanis, et al

Neuropsychiatric Disease and Treatment 2008, 4:477-479

Published Date: 11 April 2008

A review of ramelteon in the treatment of sleep disorders

David N Neubauer

Neuropsychiatric Disease and Treatment 2008, 4:69-79

Published Date: 8 February 2008

Prevalence of eating disorders and eating attacks in narcolepsy

Norbert Dahmen, Julia Becht, Alice Engel, Monika Thommes, Peter Tonn

Neuropsychiatric Disease and Treatment 2008, 4:257-261

Published Date: 8 February 2008

A neuropsychiatric review of pediatric obsessive-compulsive disorder: etiology and efficacious treatments

Adam B Lewin, Eric A Storch, Gary R Geffken, Wayne K Goodman, Tanya K Murphy

Neuropsychiatric Disease and Treatment 2006, 2:21-31

Published Date: 15 March 2006

A review of SPECT studies in psychiatry in China

Shenxun Shi, Liang Shu

Neuropsychiatric Disease and Treatment 2006, 2:43-51

Published Date: 15 March 2006